Galaxy Therapeutics announced it has completed enrollment in the SEAL IT pivotal trial evaluating the company’s saccular ...
CorMedix Therapeutics announced interim results for the company’s ongoing real-world study of its DefenCath (taurolidine ...
The American College of Cardiology (ACC) announced that a new scientific statement on the management of peripheral artery dise ...
Shape Memory Medical Inc. announced that its Impede embolization plug product family, which previously received CE Mark approv ...
December 22, 2025—iVascular announced the initiation of the 4-NiVO clinical study, which is evaluating the efficacy and safety of its iNstroke 4 ...
Gore & Associates G.K. in Minato-ku, Tokyo, Japan, announced the first clinical use in Japan of the Gore Excluder thoracoa ...
Johnson & Johnson MedTech announced that the FDA has approved an expanded indication for the company’s TruFill n-But ...
IceCure Medical Ltd. announced that four abstracts featuring data from independent clinical studies conducted in Spain and ...
Penumbra announced the publication of a new study that showed that the use of the company’s computer-assisted vacuum thr ...
December 15, 2025—Gore & Associates announced the first implantation of its investigational Gore Ascending Stent Graft in the ARISE III trial for the treatment of an acute type A dissection. The ...
CAS plus intensive medical therapy significantly reduced 4-year stroke or death rates compared with medical therapy alone. CEA did not provide a significant additional benefit over intensive medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback